Ann: RELINT: FPH: Disclosure Directors & Senior Managers...

• Release Date: 23/12/14 17:10
• Summary: RELINT: FPH: Disclosure Directors & Senior Managers Relevant Interests
• Price Sensitive: No
• Download Document  24.88KB

					FPH
23/12/2014 17:10
RELINT
NOT PRICE SENSITIVE
REL: 1710 HRS Fisher & Paykel Healthcare Corporation Limited

RELINT: FPH: Disclosure Directors & Senior Managers Relevant Interests

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  23-Dec-14
Date of last disclosure:   30-Sep-14

Director or senior manager giving disclosure
Full name(s):  Winston Richard FONG
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Vice President ICT

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial Ownership
For that relevant interest-
Number held in class before acquisition :  10,866
Number held in class after acquisition:  10,963
Current registered holder(s):  Winston Richard FONG
Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  19-Dec-14
Nature of transaction:  Acquisition of 97 Ordinary shares under the
Company's Dividend Reinvestment Plan.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  $587.16
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:  Ordinary shares
Nature of relevant interest:  Beneficial
For that relevant interest,-
Number held in class:  10,963
Current registered holder(s):  Winston Richard FONG
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  23-Dec-14
Date of last disclosure:   11-Jul-14

Director or senior manager giving disclosure
Full name(s):  Antony John Carter
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Director

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial ownership
For that relevant interest-
Number held in class before acquisition :  "(a)  4,816
(b)  63,814 "
Number held in class after acquisition :  "(a) 4,859
(b)  64,383 "
Current registered holder(s):  "(a)  FNZ Custodians as custodians for Antony
Carter No 2  Family Trust;
(b)  Loughborough Investments Limited - as Director of Company."
Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Date of transaction:  19-Dec-14
Nature of transaction:  "(a) Acquisition of 43 Ordinary shares under the
Company's dividend reinvestment plan.
(b) Acquisition of 569 Ordinary shares under the Company's dividend
reinvestment plan."
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
NZ$260.28
(b) NZ$3,444.27"
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:  Ordinary shares
Nature of relevant interest:  "(a) Benefical;
(b) Beneficial;
(c) Non-Beneficial as Director of Share Purchase Trustee Company"
For that relevant interest,-
Number held in class:  "(a) 4,859
(b) 64,383
(c) 642,774"
Current registered holder(s):  "(a)  FNZ Custodians as custodians for Antony
Carter No 2  Family Trust;
(b)  Loughborough Investments Limited - as Director of Company;
(c)  Director of Trustee Company - Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited"
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  23-Dec-14
Date of last disclosure:   11-Jul-14

Director or senior manager giving disclosure
Full name(s):  Arthur James MORRIS
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Director

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial Ownership
For that relevant interest-
Number held in class before acquisition:  8,912
Number held in class after acquisition:  8,991
Current registered holder(s):  Niloc Trust (Family Trust)
Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition:
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  19-Dec-14
Nature of transaction:  Acquisition of 79 Ordinary shares under the
Company's dividend reinvestment plan.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ$478.20
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition :
Class of quoted financial products:  Ordinary shares
Nature of relevant interest:  Beneficial
For that relevant interest,-
Number held in class:  8,991
Current registered holder(s):  Niloc Trust (Family Trust)
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  23-Dec-14
Date of last disclosure:   11-Jul-14

Director or senior manager giving disclosure
Full name(s):  Donal Paul O'DWYER
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Director

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial Ownership
For that relevant interest-
Number held in class before acquisition:  54,031
Number held in class after acquisition:  54,549
Current registered holder(s):  Donal Paul O'DWYER
Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  19-Dec-14
Nature of transaction:  Acquisition of 518 Ordinary shares under the
Company's dividend reinvestment plan.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
$3,135.55
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:  Ordinary shares
Nature of relevant interest:  Beneficial
For that relevant interest,-
Number held in class:  54,549
Current registered holder(s):  Donal Paul O'DWYER
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  23-Dec-14
Date of last disclosure:   1-Dec-14

Director or senior manager giving disclosure
Full name(s):  Michael Grenfell DANIELL
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  N/A
Position held in listed issuer:  "Managing Director/
Chief Executive Officer"

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial Ownership
For that relevant interest-
Number held in class before acquisition:  (a) 70580
Number held in class after acquisition:  (a) 71209
Current registered holder(s):  Michael Grenfell Daniell
Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  19-Dec-14
Nature of transaction:  Acquisition of 629 Ordinary shares under the
Company's Dividend Reinvestment Plan.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ$3,807.46
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not applicable
Date of the prior written clearance (if any):  Not applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:  Ordinary shares
Nature of relevant interest:  "(a) Beneficial;
(b) Beneficial;
(c)  Non-beneficial as a Director of an Employee Share Purchase Trustee
Company."
For that relevant interest,-
Number held in class:  (a) 71,209; (b) 769,109;  (c)  642,774
Current registered holder(s):  "(a) Michael Grenfell Daniell;
(b) Daniell Family Trust;
(c)  Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited."
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  23-Dec-14
Date of last disclosure:   23-Dec-14

Director or senior manager giving disclosure
Full name(s):  Michael Grenfell DANIELL
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  "Managing Director/
Chief Executive Officer"

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   "(a) Options to acquire
Ordinary shares;
(b) Ordinary shares"
Nature of the affected relevant interest(s):  Beneficial Ownership
For that relevant interest-
Number held in class before (a) exercise; (b) acquisition:  (a) 850,000; (b)
71,209
Number held in class after (a) exercise; (b) acquistion:  (a) 750,000; (b)
115,770
Current registered holder(s):  Michael Grenfell Daniell
Registered holder(s) once transfers are registered:

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: (a) One; (b) One
Details of transactions requiring disclosure-
Date of transaction:  23-Dec-14
Nature of transaction:  Cancellation of 100,000 FPH options and issue of
44,561 ordinary shares.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  NZ$Nil
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not applicable
Date of the prior written clearance (if any):  Not applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:  Ordinary shares
Nature of relevant interest:  "(a) Beneficial;
(b) Beneficial;
(c) Beneficial;
(d) Non-beneficial as a Director of an Employee Share Purchase Trustee
Company."
For that relevant interest,-
Number held in class:  "(a) 750,000; (b) 115,770;  (c) 769,109;
(d) 642,774"
Current registered holder(s):  "(a) Michael Grenfell Daniell;
(b) Michael Grenfell Daniell;
(c) Daniell Family Trust;
(d) Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited."
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
End CA:00259351 For:FPH    Type:RELINT     Time:2014-12-23 17:10:30